Loading
A phase 2 trial of regorafenib and tislelizumab in colorectal cancer, run by Beijing Friendship Hospital, now recruiting.
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer" is a phase 2, randomised interventional study registered as NCT06829355 by Beijing Friendship Hospital, with a registry enrolment figure of 52 participants, started 2025-02-11 and due to reach its primary completion in 2025-12-31. Interventions recorded: Thymalfasin (Thymosin alpha 1, Ta1); Regorafenib (BAY 73-4506); Tislelizumab (BGB-A317). Conditions listed: MCRC. Primary outcome: Progression-free survival (PFS). Colorectal eligibility wording from the registry: "* Able to sign a written informed consent form (ICF) and able to understand and comply with the requirements of this study Male or female aged 18 to 75 Histologically or cytologically confirmed advanced or metastatic colorectal adenocarcinoma Mismatch repair (MMR) protein expression or microsatellit". Sites: China. No results are recorded here; the registry entry is the source.
Shares Regorafenib, Mismatch-repair deficient (MSI-high) colorectal cancer, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Tislelizumab, Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Tislelizumab, Mismatch-repair deficient (MSI-high) colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.